Harvard Bioscience (HBIO) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Harvard Bioscience (HBIO) Misses Q4 EPS by 3c
April 30, 2015 7:02 AM EDT
HOLLISTON, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, reported financial highlights for the three months ended March 31, 2015.
Jeffrey A. Duchemin, President and Chief Executive Officer of Harvard Bioscience, stated, "Our results this quarter largely reflect the impact in foreign currency, weak sales in the academic and government markets and weather in the Northeast. With approximately 35 percent of our business in Europe, foreign exchange headwinds, caused by the strengthening dollar versus the euro, affected customer... More
April 30, 2015 7:02 AM EDT
HOLLISTON, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company"), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, appointed James Green as a Class I director of the Board of Directors to fill the new vacancy created by Dr. Robert Dishman's retirement from the Board. Dr. Dishman served as a Director of the Company since October 2000.
Mr. Green currently serves as President and Chief Executive Officer of Analogic Corporation, a leading publicly held advanced medical and security imaging company. From 2005 to... More
